Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. The medical device maker now ...

Boston Scientific Cuts View on Unexpected Watchman Heart Implant Challenges

Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the ...

Boston Scientific’s slowdown of Minnesota-made heart device could be bad for Twin Cities

Confusion over when and if to use the Watchman implant to reduce stroke risks in patients with irregular heartbeats is ...

BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% ...
TCTMD

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

DENVER, CO—Final 5-year data from the PROTECT AF and PREVAIL trials of the Watchman left atrial appendage (LAA) closure device (Boston Scientific) continued to show similar overall stroke prevention ...
MD&M East

Look Out Watchman, There's a New Kid on the LAAC Block

As expected, FDA has approved the Amplatzer Amulet Left Atrial Appendage Occluder to treat U.S. patients with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device will compete ...

Boston Scientific trims annual profit forecast on softer Watchman device demand

By Siddhi Mahatole July 29 (Reuters) - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, ...
TCTMD

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...